心臓手術後の直接経口抗凝固療法とワーファリンの比較試験 (DANCE)
The DANCE Trial is a multi-centre, randomized controlled trial comparing the safety of direct oral anticoagulants (DOAC) versus vitamin K antagonists (VKA) in the early period (30 days) after cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.
調査の概要
詳細な説明
Approximately 36,000 Canadian adults undergo cardiac surgery annually. Of these patients, about 10% have a prior history of atrial fibrillation (AF). In the early post-operative period after cardiac surgery, 30-60% of patients develop AF and, by the time of discharge, 32% of patients who underwent cardiac surgery have an indication for oral anticoagulation (OAC). AF is associated with a significantly higher risk of stroke, even when transient, and OAC is the standard for thromboembolic prevention in these patients. In the post-operative period, the balance of benefits and risks of OAC may differ and the safest and most effective OAC in that patient population is uncertain.
Vitamin K antagonists (VKAs), such as warfarin or coumadin, are the most used anticoagulants after cardiac surgery. In the Left Atrial Appendage Occlusion Study (LAAOS) III that recruited 4811 patients from 105 centres in 27 countries, 77% of patients with AF on OAC were discharged on a VKA after cardiac surgery. Among patients taking a DOAC preoperatively, 55% were switched to a VKA after surgery. Over the first post-operative year, most of those patients were gradually transitioned back to a DOAC. Although effective, the use of VKAs is limited by a narrow therapeutic index requiring frequent international normalized ratio (INR) measurements to ensure appropriate levels of anticoagulation. This key limitation leads to non-compliance and discontinuation. In addition, in the first 3 months after cardiac surgery, time in the therapeutic range is low, even with close monitoring by experienced prescribers.
In the last decade, DOACs - inhibitors of factor Xa or thrombin- have become broadly used in patients with AF. Treatment with a DOAC in patients with AF has been demonstrated to yield a lower risk of stroke or systemic embolism and a similar risk of major bleeding when compared to VKAs during long-term follow-up. Moreover, DOACs are more convenient for both patients and clinicians. They have a rapid onset of effect, fixed dosage that obviates the need for regular monitoring, and few interactions with food and other medications. In the postoperative setting, DOACs may also lead to shorter length of stay and reduced costs.
The purpose of this study is to establish whether DOACs are as safe as VKAs in the first few weeks after heart surgery. The results of this study will impact the treatment of hundreds of thousands of patients in the world every year.
A subset of 910 DANCE participants with a recent bioprosthetic aortic and/or mitral valve replacement will be enrolled in the SUNDANCE substudy (Subclinical valve thrombosis in patients with surgical bioprosthetic valve replacement: An imaging substudy of the DANCE trial). SUNDANCE will examine the effects of DOACs versus VKAs on subclinical valve thrombosis and bioprosthetic valve function by conducting computed tomography (CT) scans and echocardiograms at 60 to 90 days after randomization.
研究の種類
入学 (推定)
段階
- フェーズ 3
連絡先と場所
研究連絡先
- 名前:Richard Whitlock, MD, PhD
- 電話番号:40306 905-527-4322
- メール:richard.whitlock@phri.ca
研究連絡先のバックアップ
- 名前:Emilie Belley-Cote, MD, MSc
- 電話番号:40306 905-527-4322
- メール:emilie.belley-cote@phri.ca
研究場所
-
-
Victoria
-
Fitzroy、Victoria、オーストラリア、3065
- 募集
- St Vincent's Hospital Melbourne
-
コンタクト:
- Andrew Newcomb, MD
-
主任研究者:
- Andrew Newcomb, MD
-
Parkville、Victoria、オーストラリア、3050
- まだ募集していません
- Royal Melbourne Hospital, University of Melbourne
-
コンタクト:
- Alistair Royse, MD
-
主任研究者:
- Alistair Royse, MD
-
-
-
-
Alberta
-
Edmonton、Alberta、カナダ、T6G 2C8
- 募集
- University of Alberta Hospital
-
主任研究者:
- Steven Meyer, MD
-
コンタクト:
- Steven Meyer, MD
-
-
British Columbia
-
Vancouver、British Columbia、カナダ、V6T 1Z3
- 募集
- University of British Columbia
-
主任研究者:
- Erica Wang, PharmD
-
-
Manitoba
-
Winnipeg、Manitoba、カナダ、R2H 2A6
- 募集
- St. Boniface Hospital
-
主任研究者:
- Michael Yamashita, MD
-
コンタクト:
- Michael Yamashita, MD
-
-
New Brunswick
-
Saint John、New Brunswick、カナダ、E2L4L2
- 積極的、募集していない
- Saint John Regional Hospital
-
-
Newfoundland and Labrador
-
St. John's、Newfoundland and Labrador、カナダ、A1B 3V6
- 募集
- Health Science Centre
-
主任研究者:
- Hasib Hanif, MD
-
-
Ontario
-
Greater Sudbury、Ontario、カナダ、P3E 5J1
- 募集
- Health Sciences North Research Institute
-
主任研究者:
- Bindu Bittira, MD
-
Hamilton、Ontario、カナダ、L8L 2X2
- 募集
- Hamilton General Hospital
-
コンタクト:
- Emilie Belley-Cote, MD, MSc
- 電話番号:40306 905-527-4322
- メール:emilie.belley-cote@phri.ca
-
Toronto、Ontario、カナダ、M5G 2C4
- 募集
- Toronto General Hospital
-
コンタクト:
- Vivek Rao, MD
-
主任研究者:
- Vivek Rao, MD
-
Toronto、Ontario、カナダ、M4N 3M5
- 募集
- Sunnybrook Hospital
-
コンタクト:
- Stephen Fremes, MD
-
主任研究者:
- Stephen Fremes, MD
-
-
Quebec
-
Montreal、Quebec、カナダ、H1T 1C8
- 募集
- Montreal Heart Institute
-
コンタクト:
- Philippe Demers, MD
-
主任研究者:
- Philippe Demers, MD
-
Montreal、Quebec、カナダ、H4J1C5
- 募集
- Hôpital Sacré-Coeur de Montréal
-
主任研究者:
- Hugues Jeanmart, MD
-
コンタクト:
- Hugues Jeanmart, MD
-
Québec、Quebec、カナダ、G1V 4G5
- 募集
- IUCPQ-ULaval
-
コンタクト:
- Eric Dumont, MD
-
主任研究者:
- Eric Dumont, MD
-
-
-
-
-
Bonn、ドイツ、53127
- 積極的、募集していない
- University Hospital Bonn Heart Center
-
Essen、ドイツ、45147
- まだ募集していません
- West-German Heart and Vascular Center, University of Duisburg-Essen
-
コンタクト:
- Matthias Thielmann, MD, PhD
-
主任研究者:
- Matthias Thielmann, MD, PhD
-
Hamburg、ドイツ、20246
- 募集
- University Medical Center Hamburg-Eppendorf
-
コンタクト:
- Simon Pecha, MD
-
主任研究者:
- Simon Pecha, MD
-
-
Saxony
-
Leipzig、Saxony、ドイツ、04289
- 積極的、募集していない
- Heart Center Leipzig
-
-
Thuringia
-
Jena、Thuringia、ドイツ、Germany
- 募集
- University Hospital Jena
-
コンタクト:
- Torsten Doenst, MD, PhD
-
主任研究者:
- Torsten Doenst, MD, PhD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age ≥18 years at the time of enrolment,
- Open heart surgery in the last 10 days,
- Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),
- Informed consent from either the patient or a substitute decision-maker.
Exclusion Criteria:
- Mechanical valve replacement,
- Antiphospholipid syndrome (triple positive),
- Severe renal failure (Cockcroft-Gault equation; creatinine clearance <15 ml/min),
- Known significant liver disease (Child-Pugh classification B and C),
- Left ventricular thrombus,
- Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis,
- Known contraindication for any DOAC or VKA,
- Women who are pregnant, breastfeeding, or of childbearing potential,
- Surgery including left ventricular assist device implantation or cardiac transplantation,
- Previously enrolled in this trial,
- Follow-up not possible,
- History of moderate or severe mitral valvular lesion (stenosis or regurgitation) that is not corrected during index cardiac surgery.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:階乗代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Direct Oral Anticoagulation (DOAC)
Patients in the intervention group will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician. |
Patients will receive a DOAC at doses recommended for the indication, adjusted for their renal function is required. The choice of DOAC will be at the discretion of the treating physician.
他の名前:
|
|
プラセボコンパレーター:Vitamin K Antagonist
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range. |
Patients in the control group will receive VKA once daily; the individual dose will be titrated to achieve a guideline-recommended INR range.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Major Bleeding
時間枠:30-Days post-randomization
|
Major bleeding at 30 days, defined as bleeding that results in death and/or symptomatic bleeding in a critical area or organ, bleeding into a surgical site requiring reoperation, bleeding leading to hospitalization (including presentation to an acute care facility without overnight stay) and/or bleeding that causes a drop in the hemoglobin level of 20g/L or more or that which requires the transfusion of ≥2 units of packed red blood cells or whole blood (as defined by the International Society of Thrombosis and Hemostasis) |
30-Days post-randomization
|
二次結果の測定
結果測定 |
時間枠 |
|---|---|
|
30日目と90日目の脳卒中と非中枢神経系の全身性動脈塞栓症の複合。
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
大出血
時間枠:無作為化後90日
|
無作為化後90日
|
|
ドレナージを必要とする胸水または心膜液
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
全身性動脈塞栓症
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
虚血性脳卒中
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
深部静脈血栓症
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
肺塞栓症
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
術後の入院期間
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
全死因死亡率
時間枠:無作為化後 6 か月
|
無作為化後 6 か月
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
心筋梗塞
時間枠:無作為化後 30 日および 90 日
|
無作為化後 30 日および 90 日
|
|
|
無症状の弁血栓症と臨床的に重要な大動脈弁血栓症、脳卒中または全身塞栓症との関連
時間枠:90日
|
90日
|
|
|
Minor Bleeding
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All bleeding (major plus minor)
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Valve Thrombosis
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
Hemorrhagic stroke
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Stroke
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome |
30-Days and 90-Days post-randomization
|
|
All Arterial Thrombosis/thromboembolism
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome: ischemic stroke, systemic arterial embolism, myocardial infarction, valve thrombosis |
30-Days and 90-Days post-randomization
|
|
Quality of Life - EQ-5D-5L
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome: Measured by The EQ-5D-5L Questionnaire |
30-Days and 90-Days post-randomization
|
|
Patient Satisfaction with Anticoagulant treatment
時間枠:30-Days and 90-Days post-randomization
|
Tertiary outcome: Assessed by the Perception of Anticoagulant Treatment Questionnaire |
30-Days and 90-Days post-randomization
|
|
Subclinical Valve Thrombosis on CT scan
時間枠:60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Mean Aortic Valve g=Gradient on echocardiogram
時間枠:60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
|
Aortic Valve Reintervention
時間枠:60 to 90-Days post-randomization
|
Substudy outcome |
60 to 90-Days post-randomization
|
協力者と研究者
捜査官
- 主任研究者:Emilie Belley-Cote, MD, MSc、McMaster University
出版物と役立つリンク
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- DANCE-2020
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
We will establish a plan for the full-scale study but there is no plan to make IPD available to other researchers.
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。